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OPTN and UBQLN2, in which mutations caused loss or 
gain of protein interactions. Several of the identified inter-
actomes showed a high degree of overlap: shared binding 
partners of ATXN2, FUS and TDP-43 had roles in RNA 
metabolism; OPTN- and UBQLN2-interacting proteins 
were related to protein degradation and protein transport, 
and C9orf72 interactors function in mitochondria. To con-
firm that this overlap is important for ALS pathogenesis, 
we studied fragile X mental retardation protein (FMRP), 
one of the common interactors of ATXN2, FUS and TDP-
43, in more detail in in vitro and in vivo model systems 
for FUS ALS. FMRP localized to mutant FUS-containing 
aggregates in spinal motor neurons and bound endogenous 
FUS in a direct and RNA-sensitive manner. Furthermore, 
defects in synaptic FMRP mRNA target expression, neu-
romuscular junction integrity, and motor behavior caused 
by mutant FUS in zebrafish embryos, could be rescued by 
exogenous FMRP expression. Together, these results show 
that interactomics analysis can provide crucial insight into 
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ALS disease mechanisms and they link FMRP to motor 
neuron dysfunction caused by FUS mutations.
Keywords Amyotrophic lateral sclerosis · FMRP  · FUS · 
C9orf72 · Motor neuron · TDP-43
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease characterized by the loss of upper and lower 
motor neurons resulting in progressive muscle weakness 
and finally death due to respiratory failure. Median survival 
is 3–5 years after symptom onset and the only treatment 
available is riluzole, which increases life expectancy with 
on average 3 months. More effective therapeutic strategies 
for ALS are needed, but their design requires further insight 
into the pathogenic mechanisms underlying this disease.
Work during the past several years has significantly 
increased our understanding of the genetic basis of ALS 
and has led to the identification of disease-causing muta-
tions in various genes including chromosome 9 open read-
ing frame 72 (C9orf72), fused in sarcoma (FUS), optineu-
rin (OPTN), profilin 1 (PFN1), sequestosome 1 (SQSTM1), 
superoxide dismutase 1 (SOD1), TANK-binding kinase 1 
(TBK1), TAR DNA-binding protein 43 (TARDBP), ubiqui-
lin 2 (UBQLN2), vesicle-associated membrane protein-
associated protein B and C (VAPB) and valosin-containing 
protein (VCP) [65]. In addition, defects in genes such as 
Ataxin-2 (ATXN2) and non-imprinted in Prader–Willi/
Angelman syndrome 1 (NIPA1) were shown to affect dis-
ease susceptibility, onset or progression [4, 19]. These 
genetic findings have triggered the identification of cellu-
lar defects contributing to ALS pathogenesis, e.g., protein 
misfolding, mitochondrial dysfunction, oxidative stress, 
cytoskeletal alterations, and dysregulation of RNA metab-
olism [69]. A pathological hallmark of ALS is the pres-
ence of protein inclusions in degenerating motor neurons. 
The molecular signatures of these inclusions have in part 
been characterized [5] and show a remarkable overlap 
with genetic findings. For example, TDP-43, OPTN and 
UBQLN2 are common constituents of ALS-associated 
protein inclusions, while mutations in TARDBP, OPTN 
and UBQLN2 occur in ALS patients [18, 53, 75]. How-
ever, while only a relatively small number of patients carry 
mutations in these genes, TDP-43 and other proteins local-
ize to aggregates in a large number of patients [5]. These 
observations hint at a general role for these proteins in ALS 
pathogenesis. However, for many genetic defects and ALS-
associated proteins it remains incompletely understood 
how they contribute to the development of motor neuron 
degeneration and ALS.
Recent studies show that identification of protein bind-
ing partners of proteins associated with ALS is a fruitful 
approach for characterization of the pathological mecha-
nisms underlying this disease [21, 23, 28, 47, 52, 76, 90, 
93]. For example, interactomics analyses have recently 
implicated survival motor neuron (SMN) and U1-snRNP 
in ALS pathogenesis associated with FUS mutations [28, 
76, 90]. Interestingly, the few reported interactomes of 
ALS-associated proteins contain interactors that are known 
to harbor mutations in patients. For example, FUS inter-
actomes reported so far contain heterogeneous nuclear 
ribonucleoprotein (hnRNP) A1 and hnRNPA2B1, while 
the genes encoding these proteins contain disease-causing 
mutations in a select group of patients [44]. This observa-
tion highlights a potential for interactome analysis to iden-
tify novel ALS-associated proteins. Further, it underlines 
the fact that these proteins participate in overlapping pro-
tein complexes and thus may affect related cellular pro-
cesses. Such convergence at the molecular and cellular 
level is interesting from a therapeutic perspective as it may 
enable the design of therapies that target larger cohorts of 
patients.
To provide further insight into the pathogenic mecha-
nisms underlying ALS and to determine the extent to 
which ALS-associated proteins share binding partners, we 
performed interactomics analyses for six ALS-associated 
proteins in neuronal cells: ATXN2, C9orf72, FUS, OPTN, 
TDP-43 and UBQLN2. Analyses were performed in par-
allel to minimize experimental variability. Because gene 
mutations may lead to gain- or loss-of-function phenotypes 
and changes in subcellular localization of the affected pro-
tein, interactomes were determined for wild-type proteins 
or proteins carrying an ALS-associated mutation (except 
C9orf72). Our study reveals a striking overlap between the 
interactomes of ATXN2, FUS, and TDP-43, and the inter-
actomes of OPTN and UBQLN2, while interacting proteins 
for C9orf72 were distinct. Furthermore, mutations in OPTN 
and UBQLN2 altered interactome composition. Finally, 
in-depth characterization of one of the shared interactors 
of ATXN2, FUS, and TDP-43, identified a functional link 
between ALS mutant FUS and fragile X mental retardation 
protein (FMRP), a translational repressor that controls syn-
aptic function. Our finding that FMRP rescues defects in 
neuromuscular junction (NMJ) morphology and aberrant 
motor behavior caused by mutant FUS in zebrafish together 
with recent work linking FMRP and TDP-43 [14] identifies 
FMRP as a shared component of the pathogenic mecha-
nisms downstream of multiple ALS-associated proteins.




For the co-immunoprecipitation of endogenous protein 
complexes, N2A or NSC-34 cells from one 10-cm dish 
were lysed in 150 μl lysis buffer [20 mM Tris–HCl pH 
7.5, 150 mM NaCl, 1 % NP-40, 10 % glycerol, complete 
protease inhibitor cocktail (Roche)], incubated on ice for 
10 min and centrifuged at 13,200 rpm for 10 min at 4 °C. 
Lysates were incubated for 1 h at 4 °C using 1 μg antibod-
ies. Detailed information on antibodies and plasmids used 
can be found in the Supplementary Material. Samples were 
incubated with protein A or protein G magnetic beads for 
30 min followed by 4 washes in lysis buffer. Precipitated 
proteins were eluted by boiling in NuPage LDS sample 
buffer containing 10 mM DTT for 5 min at 90 °C. For 
RNA dependency experiments, lysates were first treated 
with RNAse A (Roche) for 30 min at 4 °C. Recombinant 
FUS (Origene) and FMRP (Abnova) proteins were mixed 
in buffer (10 % glycerol, 0.5 % NP40, 100 mM glycine, 
25 mM Tris–HCl, pH 7.4) and incubated for 1 h with pro-
tein A agarose beads pre-incubated with rabbit anti-FUS 
antibody. Immunoprecipitation was performed as described 
above. For RNA dependency experiments, total RNA was 
isolated from HEK293 cells using the RNAeasy mini kit 
(Qiagen) according to the manufacturer’s instructions and 
added to the protein mixture at concentrations ranging from 
0.1 to 62.5 ng/μl. For the generation of crude mitochondrial 
fractions, N2A cells were homogenized in homogenization 
buffer [0.25 M sucrose, 0.2 mM EDTA, 20 mM HEPES 
pH 7.4, complete protease inhibitor cocktail (Roche)] and 
a pellet containing crude mitochondria was obtained after 
differential centrifugation of the lysate.
Proteins were separated in a SDS-PAGE gel and trans-
ferred onto nitrocellulose membrane (Hybond-C Extra; 
Amersham). Membranes were incubated in blocking 
buffer (TBS, 0.05 % Tween and 5 % milk powder) for 
30 min at room temperature (RT), followed by incubation 
with the appropriate antibody overnight at 4 °C. After sev-
eral washes with TBS-T, membranes were incubated with 
appropriate peroxidase conjugated secondary antibodies in 
blocking buffer for one hour at RT followed by incubation 
with Super Signal West Dura Extended Duration Substrate 
(Pierce) and exposed to ECL films (Pierce). For quantifica-
tion of Western blots, intensity measurements of the protein 
bands were performed using ImageJ.
Biotin‑streptavidin pull down
Immunoprecipitation of biotin-tagged proteins was per-
formed as described previously [16, 28]. It is important to 
note that cell lysis could allow bait proteins to interact with 
proteins that they normally would not be able to bind (e.g., 
because of their localization in distinct cellular compart-
ments). While this is an important point to consider, so far 
we have performed bioIPs for >40 different bait proteins 
(including cytoplasmic, nuclear or membrane-associated 
proteins) and never found strong evidence for such post-
lysis artifacts.
In‑gel analysis and LC–MS/MS analysis
Samples were separated in a NuPAGE Novex 4–12 % Bis/
Tris gradient gel following the manufacturer’s instruc-
tions. For silver staining, gels were fixed in 50 % metha-
nol for 30 min, followed by incubation in 10 μM DTT for 
15 min and incubation in 0.1 % (w/v) AgNO3 for 20 min. 
Subsequent gels were developed using 0.25 M anhydrous 
sodium carbonate containing 0.02 % (w/v) formaldehyde. 
For mass spectrometry analysis, gels were stained using 
GelCode blue stain reagent (Pierce). Mass spectrometry 
analysis of interacting proteins was done as described 
previously [96]. Raw data were analyzed by MaxQuant 
(version 1.4.1.2) [12] as described in the Supplementary 
Material. GO analysis was performed using PANTHER 
[57].
Primary motor neuron culture, transfection 
and immunocytochemistry
All animal care and use was in line with institutional, 
national and European legislation. Mice (C57BL/6) were 
purchased from Charles River. Primary motor neurons 
were isolated from the ventral part of spinal cords of E13.5 
mouse embryos and cultured as described in the Supple-
mentary Material. After 48 h, cells were transfected using 
magnetic beads (Oz Biosciences) as described by Fallini 
et al. [20].
Primary motor neurons were fixed with 4 % PFA for 
15 min at RT, permeabilized with 0.1 % Triton X-100 in 
PBS for 5 min at RT, blocked in PBS containing 2.5 % 
BSA, and incubated with primary antibodies in BSA sup-
plemented with 5 % normal goat serum for 1 h at RT. After 
several washes in PBS, cells were incubated with a mixture 
of the appropriate Alexa Fluor®-labeled secondary anti-
bodies (Life Technologies) for 1 h at RT. Then, cells were 
washed, counterstained with 4′,6′-diamidino-2-phenylin-
dole (DAPI) (Sigma), washed extensively with PBS and 
mounted in DABCO.
Immunohistochemistry on human spinal cord samples
Consent for autopsy was obtained in concordance with 
institutional regulations. Patient and control details 
are included in Supplementary Table S3. Double 
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immunohistochemistry and double fluorescent-labeling 
were performed as described in the Supplementary Mate-
rial. Due to antibody incompatibilities we were unable to 
perform double fluorescent-labeling for all interactors. Sec-
tions were analyzed using a laser scanning confocal micro-
scope (Leica TCS Sp2, Wetzlar, Germany).
Zebrafish studies
Zebrafish were kept and maintained under standard con-
ditions. Injections were performed at the one-cell stage. 
FUS WT, FUS R521C and mCherry-FMRP were sub-
cloned into a pCS2+ vector and mRNA was transcribed 
using the mMESSAGE Machine kit (Ambion) followed 
by phenol–chloroform purification and ethanol precipi-
tation. mRNAs were diluted in RNAse free water (with 
1 % phenol-red dye) at a concentration of 75–200 ng/μl 
and were pulse-injected using a pressure ejector. Touch-
evoked escape response (TEER) was measured in devel-
opmentally normal zebrafish, as described previously 
[41].
For immunohistochemical analysis, zebrafish larvae 
were fixed in 4 % PFA overnight at 4 °C. Larvae were 
rinsed in PBS with 0.1 % tween (PBS-T) and then permea-
bilized with collagenase A (1 mg/ml) for 45 min at RT and 
stained consecutively with Alexa Fluor® 488-conjugated 
alpha-bungarotoxin and anti-SV2 antibody as described in 
the Supplementary Material.
Image analysis and statistics
For FMRP granule analysis, primary motor neurons were 
imaged using a Zeiss Axioskop2 microscope in combina-
tion with Axiovision SE64 software. For quantification 
of FMRP granules, an automated method in ImageJ was 
designed and statistical significance was tested using an 
ANOVA. For the zebrafish NMJ analysis, images were 
acquired using an Olympus Fluoview FV1000 confocal 
microscope and overlap between pre- and postsynapse was 
determined using the JACoP plugin for ImageJ [6] with 
Costes’ automatic thresholding.
Synaptosome isolation
Zebrafish embryos were collected at 72 hpf and yolk sacs 
were removed by triturating in ice-cold Ringer’s salt solu-
tion (116 mM NaCl, 2.9 mM KCl, 1.8 mM CaCl2, 5 mM 
HEPES) with 50 mM EDTA. Then, 200–500 embryos 
were homogenized per condition in homogenization buffer 
(320 mM sucrose, 4 mM HEPES supplemented with pro-
tease inhibitors) and synaptosomes were obtained after dif-
ferential centrifugation of the lysate.
Quantitative RT‑PCR
Zebrafish embryos were collected as described above and 
150–200 embryos per condition were homogenized and 
fractionated in homogenization buffer supplemented with 
2 % β-mercaptoethanol. TRIzol reagent was added to each 
fraction and total RNA was isolated. After DNAse treat-
ment, cDNA was synthesized and quantitative real-time 
PCR was performed using primers listed in the Supplemen-
tary Materials. Fractions were normalized to their respec-
tive inputs and fold changes were then calculated compared 
to non-injected controls using standard comparative ΔΔCT 
methods. Samples from three experiments were amplified 
in triplicate and results were statically analyzed using Stu-
dent’s t test.
Polysomal fractionations
Polysomal fractionations from N2A cells were performed 
using a protocol adapted from Gismondi et al. [27].
Results
Interactomics analysis of ALS‑associated proteins
Identification of protein binding partners of proteins asso-
ciated with ALS can aid the characterization of the patho-
genic mechanisms underlying this disease [21, 23, 28, 52, 
76, 77, 90]. To further dissect ALS disease mechanisms and 
to possibly unveil common disease pathways downstream 
of multiple ALS-associated proteins, we used a biotin-
streptavidin pull down system [16, 28] in combination with 
mass spectrometry to determine the interactomes of six 
ALS-associated proteins. ATXN2, C9orf72, FUS, OPTN, 
TDP-43 and UBQLN2 were selected on basis of genetic 
and pathological data. These proteins are the focus of many 
current studies on ALS pathogenesis, are localized to ALS-
associated inclusions in a large proportion of patients [5, 
43], and/or are poorly characterized at the functional level 
(C9orf72).
To identify interactors, biotin-GFP-tagged (bioGFP) 
constructs were generated for ATXN2, C9orf72, FUS, 
OPTN, TDP-43, and UBQLN2 as well as for a common 
ALS-associated mutant variant of each of these proteins 
(ATXN2 31Q, 39Q, FUS R521C, OPTN E478G, TDP-43 
M337V and UBQLN2 P497H) (Fig. 1a). Hexanucleotide 
repeat expansions in C9orf72 cause ALS but these expan-
sions are found in the non-coding part of the gene and are 
therefore not present in C9orf72 protein [17, 68]. Never-
theless, C9orf72 was included to further define its func-
tional role(s). Neuronal cells (N2A) were co-transfected 
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with plasmids encoding the bacterial biotin ligase BirA 
and one of the bioGFP-tagged constructs. Importantly, the 
subcellular localization of transfected epitope-tagged pro-
teins was indistinguishable from the reported distribution 
of their wild-type or ALS-mutated endogenous counter-
parts (Fig. 1b). Furthermore, immunoblotting showed that 
expression of epitope-tagged ATXN2, FUS, OPTN, and 
TDP-43 was equivalent to or lower than endogenous pro-
teins, while exogenous UBQLN2 was expressed at slightly 
higher levels. Endogenous expression of C9orf72 was low 
in N2A cells consistent with weak expression of C9orf72 
in other cell types [33, 83] (Fig. 1c). Biotinylated bait pro-
teins and their binding partners were captured from N2A 
cell lysates with magnetic streptavidin beads, separated on 
gel and subjected to immunoblotting with anti-GFP anti-
bodies or silver staining to confirm pull down efficiency 
(Figs. 1d, S1, S2). Following this confirmation, samples 
were subjected to mass spectrometry analysis. Identifica-
tion and quantification of proteins was carried out using 
MaxQuant software [11] and statistical analyses were per-
formed using the open PERSEUS environment. For pair-
wise comparison of GFP and WT interactomes, and WT 
and mutant interactomes, Welch’s t test statistics were 
applied with an FDR of 0.01 and S0 of 1.5 (the S0 param-
eter sets a threshold for minimum fold change). With 
these criteria, 163 interactors of ATXN2, 53 interactors 
Fig. 1  Experimental setup of interactomics analysis of six ALS-
associated proteins. a Schematic representation of bioGFP-tagged 
ATNX2, C9orf72, FUS, OPTN, UBQLN2 and TDP-43. Numbers 
indicate common ALS-associated mutations. Bio biotin-tag, CC 
coiled-coil domain, DENN differentially expressed in normal and 
neoplasia, E nuclear export signal, G-rich glycine-rich region, L 
nuclear localization signal, Lsm like-Sm domain, Lsm AD Lsm asso-
ciated domain, P Poly(A)-binding protein interacting motif, PX pro-
line XX repeat region, Q poly-glutamine stretch, QGSY glutamine/
glycine/serine/tyrosine-rich region, RRM RNA recognition motif, 
RGG arganine/glycine-rich region, ST heat shock chaperone binding 
motif, UBAN ubiquitin binding in ABIN and NEMO domain, UBL 
ubiquitin-like domain, UA ubiquitin-associated domain, WT wild-
type, Z zinc finger motif. b Immunocytochemistry for GFP on Neu-
ro2A (N2A) cells transfected with the indicated constructs (shown 
in a). Exogenous proteins show an endogenous distribution pattern. 
c Western blot analysis of lysates of N2A cells transfected with the 
indicated constructs. Tubulin is used a loading control. Exogenous 
proteins are indicated with closed arrowheads, open arrowheads indi-
cate endogenous proteins. d Overview of experimental design. N2A 
cells were co-transfected with bioGFP-tagged constructs and the bio-
tin ligase BirA. After 48 h, exogenous proteins were purified using 
magnetic streptavidin-coated beads. Purified protein complexes were 
separated using gel electrophoresis and subjected to silver staining 
to confirm equal protein loading and detection of bait and interact-
ing proteins. Mass spectrometry analysis was performed, followed 
by MaxQuant analysis and statistical analysis using PERSEUS. IB 
immunoblot. Scale bar 30 μm
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of C9orf72, 123 interactors of FUS, 33 interactors of 
OPTN, 140 interactors of TDP-43, and 104 interactors of 
UBQLN2 were identified. These interactors included both 
known and novel binding partners of the different ALS-
associated protein baits. It is important to note that some 
of the identified interactors may engage in indirect interac-
tions that require other proteins for binding to the selected 
bait proteins. Below each of the interactomes identified in 
this study is discussed in more detail.
ATXN2
ATXN2 is an RNA-binding protein that is involved in poly-
adenylation, translation, stress granule assembly and recep-
tor endocytosis [79]. Binding partners of ATXN2 identified 
in our study included the known interactors polyadenylate-
binding protein 1 (Pabpc), probable ATP-dependent RNA 
helicase DDX6 (Ddx6) [55, 63], and argonaute-2/Eif2c2 
[55] and a range of other proteins involved in RNA metab-
olism, including: hnRNPs, eukaryotic initiation factors, 
RNA helicases and splicing factors (Fig. 2a; Supplemen-
tary Table S1a). GO analysis indicated that ATXN2 binds 
proteins known to be part of the ribonucleoprotein (RNP) 
complex, stress granules, eIF3 complex and the spliceo-
some and are associated with cellular processes including 
mRNA translation, mRNA metabolic processing, splicing, 
posttranscriptional regulation and RNA localization (Sup-
plementary Table S1a). The interactors hnRNPA1, hnRN-
PA2B1, Matr3, FMRP and Prkra have previously been 
associated with neurodegenerative diseases (ALS, multi-
system proteinopathy, fragile X-associated tremor/ataxia 
syndrome (FXTAS), fragile-X syndrome (FXS) and dysto-
nia parkisonism).
C9orf72
The function of C9orf72 is largely unknown although 
homology searches identified a putative DENN domain 
[50, 92]. Intriguingly, the top hit of our interactomics anal-
ysis was Smith–Magenis syndrome chromosome region, 
candidate 8 (Smcr8), another DENN domain containing 
protein [92]. In addition, we identified a plethora of mito-
chondrial proteins including WD repeat containing protein 
41 (Wdr41), Mitochondrial import inner membrane trans-
locase subunit TIM50 (Timm50), Inner membrane protein 
mitochondrial (Immt), solute carrier family (Slc)25a3, 
Slc25a12, Slc25a5, Slc16a1, Slc25a4, ATPase family 
AAA-domain containing protein 3 (Atad3) and voltage-
dependent anion-selective channel protein 3 (Vdac3) 
(Fig. 2b; Supplementary Table S1b). This suggests a role 
for C9orf72 in mitochondrial function. In line with this 
observation, GO analysis showed enrichment for proteins 
present in the inner mitochondrial membrane and Western 
blotting detected C9orf72 in mitochondria-enriched frac-
tions (Fig. S3; Supplementary Table S1b).
FUS
FUS (also known as translated in liposarcoma (TLS)) is 
an hnRNP protein that has been associated with multiple 
steps in RNA metabolism. A large number of ALS-associ-
ated mutations in FUS target its nuclear localization signal 
(NLS) and thereby cause cytosolic mislocalization [48, 
81]. However, FUS also localizes to cytosolic aggregates 
in motor neurons of ALS patients that do not carry muta-
tions in FUS [5]. Many of the proteins found in bioGFP-
FUS protein complexes were RNA/DNA-binding proteins 
and GO analysis of all proteins found to interact with FUS 
showed a strong enrichment for categories such as RNA 
processing and splicing, mRNA metabolic process, DNA 
repair, RNA transport, RNA stability and translation. The 
cellular compartments linked to the FUS interactome were 
RNP complex, spliceosome and ribosome (Fig. 2c; Supple-
mentary Table S1c). FUS interactors identified in this study 
included previously characterized binding partners of FUS 
such as polypyrimidine tract-binding protein (Ptbp1) and 
serine and arginine-rich (SR) proteins [56]. Furthermore, 
the FUS interactome identified here showed a considerable 
overlap with previously reported FUS interactomes; e.g., 
45 % of the interactors identified in our study were also 
found by Sun et al. [28, 76, 90]. This is significant consid-
ering the fact that these studies used different methods and 
cell types to identify interactors. Finally, FUS pull down 
led to the identification of several interactors with known 
roles in motor neuron disease or other neurodegenerative 
disorders, including hnRNPA1, hnRNPA2B1, Matrin3 and 
FMRP [3, 38, 44].
OPTN
Mutations in OPTN were already known to cause primary 
open-angle glaucoma when it was found that both dominant 
and recessive mutations in OPTN cause ALS [53]. OPTN is 
an inhibitor of NF-κB signaling [97], an autophagy recep-
tor [85] and a regulator of vesicular transport associated 
with the Golgi apparatus [73]. Among the interactors of 
OPTN were the known interactors Ubiquitin (Ub), Tbk1, 
Tax1-binding protein 1 (Tax1bp1), and Sqstm1 [9, 39, 85]. 
In addition, other known regulators of NF-κB signaling and 
autophagy like TNFAIP3-interacting protein 1 (Tnip1), 
E3 ubiquitin-protein ligase RNF31 (Rnf31) and Vcp were 
detected (Fig. 2d; Supplementary Table S1d). Furthermore, 
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different members of the Nuclear protein localization pro-
tein 4 homolog (Nploc4)-Vcp-Ubiquitin fusion degrada-
tion protein 1 homolog (Ufd1l) complex were present in 
the OPTN interactome indicating a role for OPTN in the 
Endoplasmic-Reticulum Associated Protein Degradation 
(ERAD) pathway. The OPTN interactome also included the 
linear ubiquitin chain assembly complex (LUBAC) that has 
recently been implicated in ubiquitin-signaling. LUBAC 
links K63-linear ubiquitin chains to specific substrates, 
e.g. the receptor interacting protein (RIP), thereby regulat-
ing signaling cascades including NF-κB-signaling. OPTN 
competes with NF-κB essential molecule (NEMO) for 
binding polyubiquitinated RIP, thereby inhibiting NF-κB 
signaling. GO analysis revealed that OPTN interactors are 
involved in protein localization and intracellular transport 
(Supplementary Table S1d). Interestingly, three of the iden-
tified interactors, Vcp, Sqstm1 and Tbk1, have recently 
been implicated in ALS [9, 22, 25, 37].
Fig. 2  Quantitative analysis of the binding partners of six wild-type 
ALS-associated proteins. a–f Volcano plots showing interactors of 
wild-type, non-mutated forms of ATXN2 22Q (a), C9ORF72 (b), 
FUS (c), OPTN (d), TDP-43 (e) and UBQLN2 (f). Logarithmized 
ratios of relative protein intensities are plotted against the negative 
logarithmic p value from triplicate experiments (Welch’s t test; S0: 
1.5, FDR: 0.01). PERSEUS was used for statistical analysis and visu-
alization; colored dots represent significantly enriched proteins and 
the color refers to the corresponding functional category indicated at 
the right. FXR fragile-X related, MICOS mitochondrial contact site 
complex, ERAD endoplasmatic-reticulum-associated degradation
182 Acta Neuropathol (2016) 132:175–196
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TDP-43
TDP-43 was first identified as a major constituent of ALS 
cytoplasmic inclusions [62] and subsequent studies showed 
that mutations in the gene encoding TDP-43, TARDBP, 
segregate with disease in familial ALS [75]. TDP-43 is a 
DNA and RNA-binding protein that plays an important role 
in transcription and splicing. ALS-associated mutations 
in TARDBP cluster in its C-terminal glycine-rich domain. 
As reported for FUS, many DNA- and RNA-binding pro-
teins were detected in the interactome of TDP-43 (Fig. 2e; 
Supplementary Table S1e) and GO analysis revealed that 
these proteins play a role in RNA processing, gene expres-
sion, RNA splicing, posttranscriptional regulation of gene 
expression and translation. Two earlier studies investigated 
interacting proteins of TDP-43 [23, 52] and these previ-
ously reported interactomes display considerable overlap 
with the one reported in our study (60 % of the interactors 
identified in our TDP-43 pull down were also identified by 
Freibaum et al. [23] and 60 % of the interactors identified 
by Ling et al. [52] were also found by us). A number of val-
idated TDP-43 binding partners were present in our screen 
including hnRNPA2B1 and hnRNPA1 [7, 70], hnRNPH, 
hnRNPK, hnRNPQ (Syncrip), interleukin enhancer binding 
factor 3 (Ilf3) [23, 52], Matrin3 [38], Pabpc [23] and prob-
able ATP-dependent RNA helicase DDX5 (Ddx5) [42]. In 
addition, several of the identified proteins had previously 
been linked to neurodegenerative diseases like hnRNPA1, 
hnRNPA2B1, Matrin3 and FMRP.
UBQLN2
Ubiquilins form a functional link between ubiquitination 
machinery and the proteasome [45]. Indeed, many protea-
some subunits were found in the UBQLN2 interactome, as 
well as two ubiquitin ligases [E3 ubiquitin-protein ligase 
TRIM32 (Trim32) and E3 ubiquitin-protein ligase Itchy 
(Itch)] and many proteins related to the protein degradation 
pathway including ubiquilin 1 (Ubqln1), Optn, Sqstm1, 
Vcp, ubiquitin fusion degradation protein 1 homolog 
(Ufd1l) and Tbk1 (Fig. 2f; Supplementary Table S1f). As 
mentioned above, Sqstm1, Vcp and Tbk1 have been asso-
ciated with ALS, suggesting that these proteins are part of 
a common complex and may cause ALS by disruption of 
a common cellular mechanism. Interestingly, Ataxin-10 
(Atxn10) and Huntingtin-associated protein 1 (Hap1), 
proteins associated with the neurodegenerative disease 
spinocerebellar ataxia 10 (SCA10) and Huntington’s dis-
ease, respectively, were identified as UBQLN2 interactors. 
GO analysis indicated that the UBQLN2 interactome is 
enriched for proteins involved in protein catabolic process, 
the ERAD pathway and protein localization (Supplemen-
tary Table S1f).
ALS‑associated mutations alter composition of OPTN 
and UBQLN2 interactomes
Mutations may not only cause protein mislocalization or 
affect enzymatic activity but could also influence protein–
protein interactions. To determine whether the ALS-asso-
ciated mutations selected here influence protein–protein 
interactions, we compared the interactomes of wild-type 
and mutant proteins. No statistically significant differences 
were detected between the interactomes of wild-type and 
mutant ATXN2, FUS and TDP-43. However, OPTN and 
UBQLN2 wild-type and mutant proteins showed altered 
protein interaction patterns (Fig. 3a, b). This difference 
was most prominent for mutant OPTN, where interac-
tions with 13 proteins were detected for OPTN WT but 
not OPTN E478G. These interactors were Casein kinase 
II subunit alpha (Csnk2a1, Csnk2a2), Pre-mRNA-splicing 
factor ATP-dependent RNA helicase DHX15 (Dhx15), 
IgE-binding protein (Iap), cAMP-dependent protein kinase 
type I-alpha regulatory subunit (Prkar1a), Rnf31, Dolichyl-
diphospho-oligosaccharideprotein glycosyltransferase 
subunit 1 (Rpn1), Sqstm1, Tax1bp1, TBC1 domain fam-
ily member 15 (Tbc1d15), Ub, Vcp and ATPase WRNIP1 
(Wrnip1) (Fig. 3a). Other interactors that were specific for 
wild-type OPTN but that did not pass our selection crite-
ria were Protein 2410002F23Rik, BAG family molecular 
chaperone regulator 2 (Bag2), DnaJ homolog subfamily B 
member 6 (Dnajb6), FAS-associated factor 2 (Faf2), Flo-
tillin-1 (Flot1), Flotillin-2 (Flot2), Pericentriolar material 
1 protein (Pcm1), Peptidyl-prolyl cis-trans isomerase A 
(Ppia), Proteasome subunit alpha type-7 (Psma7), Ras-
related protein Rab-1A (Rab1a), RanBP-type and C3HC4-
type zinc finger-containing protein 1 (Rbck1), Sphingo-
sine-1-phosphate lyase 1 (Sgpl1), Store-operated calcium 
entry-associated regulatory factor (Tmem66) and Ufd11. 
The proteins that failed to bind mutant OPTN function in 
ubiquitin-dependent protein degradation and ER transport.
UBQLN2 P497H showed increased binding affinity for 
clathrin heavy chain 1 (Cltc) compared to UBQLN2 WT 
(Fig. 3b). Clathrin is a major component of clathrin-coated 
pits (CCPs) and vesicles involved in intracellular traffick-
ing and receptor endocytosis. In summary, our pull down 
experiments do not reveal dramatic changes in protein–pro-
tein interactions caused by ALS-associated mutations, with 
the exception of OPTN E478G.
Comparison between different interactomes reveals 
distinct and shared pathways
The experimental design of our study, i.e., parallel analysis 
of six ALS-associated proteins using an identical biochemi-
cal workflow, provided a unique opportunity to investigate 
potential overlap between ALS-associated interactomes. 
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Comparison of the different wild-type interactomes iden-
tified high overlap between ATXN2, FUS and TDP-43 
interactomes and a considerable overlap between the 
interactomes of OPTN and UBQLN2 (Fig. 3c, d). In con-
trast, the C9orf72 interactome did not overlap with any of 
the other interactomes. ATXN2, FUS and TDP-43 shared 
Fig. 3  The effect of ALS-associated mutations on interactome com-
position and overlap between different interactomes. a, b Volcano 
plots showing a comparison of the interactors of OPTN E478G and 
OPTN wild-type (WT) (a) and UBQLN2 P487H and UBQLN WT 
(b). Logarithmized ratios of relative protein intensities are plotted 
against the negative logarithmic p value from triplicate experiments 
(Welch’s t test; S0: 1.5, FDR: 0.01). PERSEUS was used for statis-
tical analysis and visualization; red dots and labels refer to proteins 
significantly altered compared to the WT interactome. c, d Venn 
diagrams showing the number of unique and overlapping interac-
tors of ATXN2, FUS and TDP-43 (c) and of OPTN and UBQLN2 
(d). Tables show GO analyses performed on the shared interactors. 
Csnk2a casein kinase II subunit alpha, Cltc clathrin heavy chain 1, 
Dhx15 Pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15, Iap IgE-binding protein, Prkar1a cAMP-dependent protein 
kinase type I-alpha regulatory subunit, Rnf31 E3 ubiquitin-protein 
ligase RNF31, Rpn1, Dolichyl-diphospho-oligosaccharideprotein 
glycosyltransferase subunit 1, Sqstm1 Sequestosome1, Tax1bp1 Tax1-
binding protein 1, Tbc1d15 TBC1 domain family member 15, Ub 
ubiquitin, Vcp valosin-containing protein, Wrnip1 ATPase WRNIP1
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69 interactors (Supplementary Table S2). These included 
RNA helicases, eIFs, Elavl proteins, hnRNPs, ribosomal 
subunits, components of the exon junction complex, splice-
osome and other RNA-binding proteins. GO analysis of the 
shared proteins identified processes such as RNA process-
ing, posttranscriptional regulation of gene expression, splic-
ing and gene expression, which is in line with the reported 
functions of ATXN2, FUS and TDP-43 (Fig. 3c). The over-
lap between OPTN and UBQLN2 included Sqstm1, Vcp, 
Ubc, Tbk1 and Tax1bp1. These shared interactors have 
reported roles in autophagy and NF-κB signaling (Fig. 3d). 
Thus, ATXN2-FUS-TDP-43 and OPTN-UBQLN2 share 
interactors that are part of common cellular protein com-
plexes and are likely to affect similar cellular processes.
Common interactors of ATXN2, FUS and TDP‑43 
localize to mutant FUS aggregates
Molecular pathways shared by different ALS-associated 
proteins provide an opportunity to understand and treat ALS 
pathogenesis in larger groups of patients. To exploit this 
opportunity, we selected six interactors shared by ATXN2, 
Fig. 4  Interactors show endogenous binding to Atxn2, Fus and Tdp-
43 and cytoplasmic mislocalization following transfection of mutant 
FUS. a–c Western blot analysis of input and immunoprecipitation 
(IP) samples with the indicated antibodies following endogenous 
immunoprecipitation with antibodies against Atxn2 (a), Fus (b), or 
Tdp-43 (c) from Neuro2A (N2A) cell lysates. Asterisk indicates IgG 
band. IgG IgG control antibody. d, e Dissociated primary motor neu-
ron cultures generated from E13.5 mouse embryos were transfected 
with DNA constructs expressing GFP, FUS wild-type (WT) or FUS 
R521C and, after 2 days in culture, fixed and immunostained using 
antibodies against FMRP (d) or Upf1 (e). DAPI staining was used to 
visualize the cell nucleus. IB immunoblot. Scale bar 30 μm (d, e)
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FUS and TDP-43 on the basis of interactome abundance 
scores, literature and availability of experimental tools 
(FMRP, Upf1, Caprin1, HuD (Elavl4), Pabpc4, and Dhx9). 
First, co-immunoprecipitation was used to confirm the 
binding of these interactors to endogenous ATXN2, FUS 
and TDP-43 (Fig. 4a–c). One model to explain how ALS 
Fig. 5  Interactors show cytoplasmic mislocalization following trans-
fection of mutant FUS (continued). a–d Dissociated primary motor 
neuron cultures generated from E13.5 mouse embryos were trans-
fected with DNA constructs expressing GFP, FUS wild-type (WT) 
or FUS R521C and, after 2 days in culture, fixed and immunostained 
using antibodies against Caprin1 (a), HuD (b), Pabpc4 (c) or Dhx9 
(d). DAPI staining was used to visualize the cell nucleus. Scale bar 
30 μm (a–d)
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mutations cause neuron degeneration is that mutant proteins 
sequester their interactors into aggregates thereby causing 
their depletion and defects in specific cellular processes (e.g. 
[28, 60]). Therefore, we next determined whether Fmrp, 
Upf1, Caprin1, HuD, Pabpc4 or Dhx9 show an altered dis-
tribution in the presence of mutant FUS. Several ALS-asso-
ciated mutations in FUS cause robust cytosolic mislocaliza-
tion and formation of inclusions, in experimental settings or 
human motor neurons, respectively (e.g. [28, 29, 31, 48, 81, 
82, 91]). GFP, wild-type FUS or FUS R521C were trans-
fected in primary mouse motor neurons and subjected to 
immunocytochemistry for FUS and the different interactors 
at 2 days in vitro (DIV2). Following transfection of FUS 
R521C condensed accumulations of mutant FUS protein 
were detected in the cytoplasm of motor neurons that were 
clearly distinct from the weak, homogeneous cytoplasmic 
distribution observed for wild-type FUS. In line with their 
ability to bind FUS, all interactors were detected in mutant 
FUS cytoplasmic accumulations in primary motor neurons 
and showed a change in their cytoplasmic distribution com-
pared to wild-type FUS neurons (Figs. 4d, e, 5). To assess 
whether a similar colocalization occurs in ALS patients, 
we performed immunohistochemistry for FUS and each of 
the six interactors on spinal cord sections from two patients 
harboring a FUS mutation (R521C) (Supplementary Table 
S3). Expression of FMRP, UPF1, CAPRIN1 and HUD, but 
not of PABPC4 and DHX9, was observed in mutant FUS 
inclusions in spinal motor neurons (Fig. S4; Supplementary 
Table S4) (70–85 % of FUS inclusions displayed immunola-
beling for interactors). Because we confirmed FMRP, UPF1, 
CAPRIN1 and HUD as shared interactors of FUS and TDP-
43 (Fig. 4b, c), we next asked whether these proteins also 
localize to TDP-43-positive inclusions. Indeed, CAPRIN1, 
FMRP and HUD were detected in phospho-TDP-43 inclu-
sions in spinal motor neurons in ALS patients (Fig. S5, S6; 
Supplementary Table S3) (80–100 % of pTDP-43 inclusions 
displayed immunolabeling for interactors). Thus, FMRP, 
Caprin1 and HuD bind endogenous FUS and TDP-43, and 
colocalize with mutant FUS and TDP-43 in aggregate-like 
structures in spinal motor neurons. Of these interactors, 
FMRP and HuD have been implicated recently in TDP-
43-induced motor neuron degeneration [2, 14, 20, 34]. To 
examine whether these proteins are indeed components of 
shared pathways downstream of multiple ALS-associated 
proteins and to further characterize their role in ALS patho-
genesis, we selected one of these candidates, FMRP, for fur-
ther functional studies in relation to FUS mutations. 
FUS‑FMRP binding is direct and regulated by RNA
FMRP is encoded by the FMR1 gene. Expansions of more 
than 200 CGG repeats in the 5′UTR of FMR1 cause FXS 
and an intermediate repeat length of 50–200 repeats causes 
FXTAS, a late-onset neurodegenerative disorder. FMRP is a 
translational repressor with many different mRNA targets in 
neurons and plays an important role in synapse formation, 
including NMJ development and plasticity [95].
First, we used co-immunoprecipitation to confirm that 
Fus and Fmrp interact in motor neuron-like NSC-34 cells 
and primary cortical neurons (Fig. 6a, b). FUS and FMRP 
associate with many RNAs and other RNA-binding pro-
teins. Thus, their interaction may be indirect and mediated 
by other proteins or RNAs. However, immunoprecipitation 
of recombinant FUS and FMRP proteins revealed a direct 
interaction in the absence of any other proteins, RNA mol-
ecules or cellular components (Fig. 6c). This indicates that 
FUS and FMRP can interact directly. To determine which 
region(s) of FUS mediate the interaction with FMRP, a 
series of FUS deletion mutants was generated and used in 
co-immunoprecipitation experiments. Full-length FUS and 
truncation mutants lacking the N-terminal QGSY region 
(Δ1–165) or the glycine-rich region (Δ165–276) bound 
FMRP. In contrast, FUS mutants lacking the C-terminal 
RGG-rich domain (Δ285–372) or the RNA recognition 
motifs (Δ360–501) did not interact with FMRP (Fig. 6d, 
e). Both FUS and FMRP are RNA-binding proteins and 
bind to and regulate many different RNAs [15, 32, 49]. We 
therefore investigated whether RNA modulates binding 
of FMRP to FUS. Interestingly, RNase treatment induced 
an increased interaction between Fus and Fmrp (441 % of 
Fig. 6  Biochemical characterization of FMRP-FUS binding. a 
FMRP pull down samples (IP) from NSC-34 cells were immunoblot-
ted with the indicated antibodies. IgG was used as a negative control. 
b IP of Fus from E14 primary mouse cortical neurons. Input and IP 
samples were analyzed with the indicated antibodies. Asterisk indi-
cates IgG band. c Recombinant FUS and FMRP proteins were mixed 
and immunoprecipitated with anti-FUS antibodies. Samples were 
analyzed with the indicated antibodies. d Neuro2A (N2A) cells were 
transfected with bioGFP-tagged FUS deletion constructs (indicated 
in e) and immunoprecipitated using streptavidin beads (IP). Sam-
ples were immunoblotted and probed with the indicated antibodies. 
e Schematic overview of bioGFP-tagged FUS deletion constructs 
used in d. Bio biotin-tag, E nuclear export signal, G rich glycine-rich 
domain, L nuclear localization signal, RRM RNA recognition motif, 
RGG arganine/glycine-rich region, QGSY glutamine/glycine/serine/
tyrosine-rich region, WT wild-type, Z zinc finger motif. f Total cell 
lysates were treated with RNase (+) and immunoprecipitated (IP) 
with IgG (control) or anti-Fus antibodies. Samples were analyzed 
with the indicated antibodies. g Recombinant FMRP and FUS pro-
teins were mixed and RNA was added in increasing concentrations. 
Protein mixtures were incubated and immunoprecipitated with anti-
FUS antibody and subjected to immunoblotting with the indicated 
antibodies. h Schematic summary illustrating how RNA modulates 
FUS-FMRP binding. FUS and FMRP bind to each other and are 
both able to bind RNA (left panel). The interaction between FUS and 
FMRP decreases with increasing RNA concentrations (middle panel). 
Vice versa, degradation of RNA enhances the interaction between 
FUS and FMRP (right panel). IB immunoblot, IC input control
▸
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RNase negative condition, p = 0.039) (Fig. 6f). To examine 
this effect of RNA in more detail, purified FUS and FMRP 
proteins were co-immunoprecipitated in the presence of an 
increasing amount of RNA. In line with the results from the 
RNase treatment, RNA application inhibited FUS-FMRP 
binding in a concentration-dependent manner (0.1 ng/
μl = 70.4 %, p = 0.27; 0.5 ng/μl = 56.5 %, p = 0.08; 
2.5 ng/μl = 23.3 %, p = 0.007; 12.5 ng/μl = 11.6 %, 
p = 0.003 and 62.5 ng/μl = 4.6 %, p = 0.002 of FUS-
FMRP binding at 0 ng/μl RNA) (Fig. 6g). Together, these 
findings identify endogenous and direct binding of FUS 
and FMRP. Further, they suggest that this interaction can be 
modulated by RNA (Fig. 6h).
Exogenous FMRP rescues neuromuscular junction 
and locomotor defects induced by ALS mutant FUS
Mutant FUS expression causes defects in synaptic transmis-
sion at the NMJ in zebrafish [1]. Similarly, loss of the Dros-
ophila homolog of FMRP, dFXR, leads to NMJ defects in 
Drosophila, possibly through upregulation of the MAP1B 
homolog Futsch [95]. Interestingly, recent work identifies 
both Futsch and FMRP as modifiers of TDP-43-depend-
ent toxicity in Drosophila [13, 14]. Here, we investigated 
whether FMRP is also able to modulate mutant FUS-
induced ALS phenotypes in vivo, using zebrafish embryos 
as a model. First, we further characterized NMJ defects 
Fig. 7  Exogenous FMRP 
rescues NMJ and locomotion 
defects caused by mutant FUS. 
a Western blot analysis of 72 
hpf zebrafish embryo lysates 
using antibodies against human 
FUS or FMRP following injec-
tion of FUS WT, FUS R521C 
and/or FMR1 RNAs. Tubulin 
is used as a loading control. 
NIC non-injected control. 
b Representative images of 
neuromuscular junctions 
(NMJ) in 72 hpf NIC zebrafish 
embryos or following injection 
of FUS WT, FUS R521C, and 
FUS R521C and FMR1 RNAs. 
Anti-synaptic vesicles 2 (SV2) 
and anti-bungarotoxin (BTX) 
were used to label the pre- and 
postsynaptic compartments. 
Arrowheads indicate absence 
of colocalization between SV2 
and BTX staining. c Quantifica-
tion of the Pearson’s correlation 
coefficient for overlap between 
immunolabeling for pre- and 
post-synaptic markers, as shown 
in b. n = 20 per condition. IB 
immunoblot. d Quantification of 
touch-evoked escape responses 
(TEER) in zebrafish embryos 
at 72 hpf following injection 
of the indicated RNAs. Data is 
obtained over five experiments 
with n = 267 for NIC, n = 182 
for FUS WT, n = 163 for FUS 
R521C and n = 111 for FUS 
R521C + FMR1. *p < 0.05, 
**p < 0.01, Fisher’s exact test. 
Scale bar 20 μm
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induced by mutant FUS to extend previous electrophysi-
ological studies revealing abnormal synaptic transmission. 
Injected embryos were immunostained at 72 hpf with anti-
synaptic vesicles 2 (SV2) antibodies, to stain the presynap-
tic compartment of NMJs, and alpha-bungarotoxin (BTX), 
to detect the postsynaptic compartment (Fig. 7a, b). As 
expected, in NIC and FUS WT injected embryos, consider-
able overlap was observed between pre- and postsynaptic 
staining (NIC: R2 = 0.46, FUS WT: R2 = 0.46, p = 0.91) 
(Fig. 7b, c). However, injection of FUS R521C caused a 
significant decrease in the overlap between pre- and post-
synaptic markers (FUS R521C: R2 = 0.39, p < 0.01), 
hinting at a loss of NMJ integrity. We then asked whether 
co-expression of FMRP and FUS R521C would restore 
abnormalities in NMJ morphology. Indeed, co-expression 
of FMRP with FUS R521C restored NMJ defects induced 
by FUS R521C (Fig. 7a–c). Overlap of pre- and postsyn-
aptic markers was similar to NIC and FUS WT, indicating 
normal NMJ integrity (FUS R521C + FMR1: R2 = 0.46, 
p = 0.86) (Fig. 7c).
To investigate the functional consequence of diminished 
NMJ integrity, we assessed zebrafish locomotion at 72 hpf 
(Fig. 7d). Developing zebrafish normally respond to touch 
by swimming away from the touch stimulus (known as 
the touch-evoked escape response, TEER). A low number 
of NIC or FUS WT larvae showed abnormal TEER (NIC: 
0.37 %, FUS WT: 0.55 %, p = 0.99). In contrast, FUS 
R521C injection led to a significantly higher number of lar-
vae with abnormal TEER (FUS R521C: 3.68 %, p < 0.05). 
In line with the ability of exogenous FMRP to restore NMJ 
integrity, zebrafish larvae co-injected with FUS R521C 
and FMRP displayed normal TEER. These data show that 
FMRP overexpression rescues mutant FUS-induced ALS 
phenotypes.
FUS R521C induces increased synaptic expression 
of the FMRP target MAP1B
Our previous work demonstrated that sequestration of 
SMN in mutant FUS aggregates causes an axonal deple-
tion of SMN and defects in axonal morphology [28]. This 
study indicates that FMRP is also captured in mutant FUS 
aggregates. Therefore, we assessed whether axonal FMRP 
levels were decreased in primary motor neurons transfected 
with FUS R521C (as shown for Smn). However, quantifica-
tion of the number of endogenous FMRP granules did not 
reveal differences between neurons transfected with GFP, 
FUS WT or FUS R521C (Fig. S7). As the subcellular dis-
tribution of FMRP appeared unaltered by mutant FUS, we 
next examined whether FMRP’s function as a regulator of 
local translation at synaptic sites was affected. Disruption 
of the repressive effect of FMRP on local translation could 
lead to increased translation of FMRP target mRNAs. To 
study this model, we used zebrafish embryos and focused 
on a well-characterized FMRP target, MAP1B. Consistent 
with our observation in transfected primary motor neurons, 
total FMRP protein levels were unchanged in zebrafish 
embryos expressing FUS R521C (Fig. 8a, b). Similarly, 
total expression of Map1b was unaffected (Fig. 8c). How-
ever, because FMRP regulates local translation at synaptic 
sites, we next examined Map1b protein levels in the syn-
aptosomal compartment. Synaptosomes were isolated from 
injected zebrafish and analyzed by Western blot (Fig. S8). 
This analysis revealed a marked increase in synaptic Map1b 
levels following mutant FUS expression (Fig. 8d–f). Impor-
tantly, co-injection of FMRP RNA normalized enhanced 
Map1b levels induced by mutant FUS (Fig. 8d–f). Q-PCR 
analysis of total and synaptosomal fractions did not reveal 
changes in the mRNA expression of Map1b (Fig. 8g, h). 
Together, these data suggest that mutant FUS may impair 
translational repression of FMRP at the synapse, thereby 
increasing protein levels of FMRP targets such as MAP1B.
Discussion
Our knowledge of the genetic etiology of ALS has 
increased significantly over the past years. However, our 
understanding of the molecular and cellular mechanisms 
underlying this disease is still incomplete. To further dis-
sect the pathogenic mechanisms of ALS, we combined pro-
tein pull down and mass spectrometry approaches to define 
the interactomes of six ALS-associated proteins (WT and 
mutant forms). Experiments for different bait proteins 
were carried out in parallel and in triplicate resulting in the 
specific identification of several known and many novel 
interactors. Our data suggest that several different ALS-
associated proteins act through common cellular pathways 
and that the ALS-associated mutations selected by us only 
affect interactome composition for OPTN and to a lesser 
extent for UBQLN2. In addition, our findings implicate 
FMRP, one of the common interactors of ATXN2, FUS, and 
TDP-43, in ALS pathogenesis caused by FUS mutations.
Common pathways downstream of ALS‑associated 
proteins
ATXN2, FUS and TDP-43
Our study shows that the interactomes of ATXN2, FUS 
and TDP-43 and those of OPTN and UBQLN2 share many 
binding partners. This suggests that these ALS-associated 
proteins contribute to common protein complexes and 
could regulate motor neuron viability or function via the 
same or similar cellular mechanisms. Furthermore, shared 
interactors of ATXN2, FUS and TDP-43 included other 
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ALS-associated proteins such as Matrin3, hnRNPA1 and 
hnRNPA2B1, supporting the idea that many different 
ALS-associated proteins may cause disease via a common 
mechanism. The observation that ALS-associated muta-
tions did not significantly alter the composition of ATXN2, 
FUS and TDP-43 interactomes indicates that the patho-
genic effects of these select mutations may not be medi-
ated by a complete loss of protein–protein interactions. 
However, it is plausible that mutations induce subtle but 
detrimental changes in protein–protein interactions that are 
not detected in our experimental setup. Our previous work 
and that of others demonstrates effects of ALS-associated 
mutations on protein–protein interactions [8, 26, 28, 52, 
76, 88, 93]. Nevertheless, it is known that mutations also 
have other effects such as on subcellular localization (e.g., 
mutations in FUS) or aggregation propensity (e.g., muta-
tions in TDP-43) of proteins [36]. Protein mislocalization 
or aggregation can lead to sequestration of binding partners 
Fig. 8  Synaptosomal expression of Map1b is increased by mutant 
FUS in vivo. a Total lysates were generated from 150 to 300 72 hpf 
zebrafish embryos injected with the indicated RNAs and subjected 
to immunoblotting with antibodies detecting endogenous Map1b 
and FMRP expression. Exogenously expressed human FMRP is not 
visible in this blot. NIC non-injected control, WT wild-type. b, c 
Quantification of band intensities as in a from at least 3 independent 
experiments. d Synaptosomal fractions were generated from 150 to 
300 72 hpf zebrafish embryos injected with the indicated RNAs and 
subjected to immunoblotting with antibodies detecting endogenous 
Map1b, FMRP and Sv-2 expression. Exogenously expressed human 
FMRP is not visible in this blot. e, f Quantification of band intensi-
ties as in d from at least three independent experiments. *p < 0.05, 
n.s. = non significant, one-way ANOVA. g, h Quantitative RT-PCR 
for Map1b on total (g) or synaptosomal (h) RNA generated from 72 
hpf zebrafish embryos injected with the indicated RNAs. Data are 
represented as mean ± SEM. IB immunoblot
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resulting in their unavailability at their normal cellular site 
of action. In further studies, it will therefore be important 
to determine which of the binding partners identified here 
aberrantly localizes to ATXN2-, FUS- or TDP43-positive 
aggregates, such as shown in this study for FMRP, HuD, 
UPF1 and CAPRIN1.
Interacting proteins that were shared by ATXN2, FUS 
and TDP-43 included proteins involved in stress granule 
formation, as well as components of the spliceosome, ini-
tiation factors, ribosomal subunits and hnRNPs. In addition 
to shared interactors, each bait also bound a set of specific 
proteins. For example, FUS, but not ATXN2 or TDP-43, 
bound a number of proteins involved in DNA repair. This 
is in line with recent data implicating FUS in this process 
[54, 72, 84]. Our data confirm and extend these findings by 
revealing that FUS may be part of a DNA repair complex 
consisting of Histone H2AX (H2afx), DNA ligase 3 (Lig3), 
Parp1, Poly (ADP-ribose) polymerase 2 (Parp2), DNA pol-
ymerase beta (Polb), DNA repair protein XRCC1 (Xrcc1), 
X-ray repair cross-complementing protein 5 (Xrcc5), and 
X-ray repair cross-complementing protein 6 (Xrcc6). From 
a therapeutic perspective, proteins that bind several differ-
ent ALS-associated proteins are interesting as they may 
provide a means for developing treatments aimed at larger 
groups of patients. However, interactors only binding a spe-
cific ALS protein are still valuable as they can help to pro-
vide insight into how ALS pathogenesis develops in spe-
cific subsets of patients and could be a starting point for the 
development of personalized medicine approaches.
OPTN and UBQLN2
In line with previous work, the OPTN interactome was 
composed of proteins playing a dual role in autophagy and 
NF-κB signaling. Interactors detected for UBQLN2 cor-
responded well with its known role in the ubiquitin-pro-
teasome system [45] and supported its suggested roles in 
ERAD [88], endosomal trafficking [61, 64], NF-κB sign-
aling and autophagy [64, 66, 85]. Significant overlap was 
detected between the interactomes of OPTN and UBQLN2. 
In line with previous work localizing both proteins to 
endosomal and autophagic vesicles [64], both OPTN and 
UBQLN2 bound Rab1, Rab6 and Tbc1d15. However, the 
most striking overlap between the OPTN and UBQLN2 
interactomes included regulators of autophagy including 
Sqstm1, Tax1bp1, Tbk1 and Vcp, which also play a role in 
NF-κB signaling. Some of these interactions were reported 
previously (OPTN-SQSTM1 [85], OPTN-TBK1 [59], 
TBK1-SQSTM1 [67], VCP-ubiquilins [51], but our study 
is the first to show that all these proteins are part of a com-
mon complex. The observation that Sqstm1, Tbk1 and Vcp 
are shared interactors of OPTN and UBQLN2 is intriguing 
as mutations in these genes have been associated with ALS 
[9, 22, 25, 37]. Future analyses of the interactomes of wild-
type and mutant SQSTM1, TBK1 and VCP are needed to 
pinpoint how these proteins cooperate in a common com-
plex with OPTN and UBQLN2 and how alterations in 
this complex may lead to ALS or other neurodegenerative 
diseases.
In contrast to ATXN2, FUS and TDP-43, mutations in 
OPTN and, to a lesser extent, UBQLN2 induced loss or 
strengthening of specific protein–protein interactions. 
We found that the E478G mutation in OPTN causes loss 
of binding to 13 interactors, while interactions with other 
proteins, e.g., Tbk1, 14-3-3 proteins or dynein, were unaf-
fected. A number of different processes are disrupted by 
the E478G mutation in OPTN, including TNF-α-induced 
NF-κB signaling [53], Salmonella autophagy [85], 
autophagic clearance of damaged mitochondria [87], and 
endosomal vesicle formation [64]. Our data suggest that 
these defects may result from the inability of OPTN E478G 
to bind specific interactors. The location of the E478G 
mutation in the ubiquitin-binding domain of OPTN sup-
ports the idea that the interactions influenced by this muta-
tion may be ubiquitin-dependent. Mutant UBQLN2 P497H 
showed increased affinity for Cltc. This supports previous 
work suggesting that the P497H mutation in UBQLN2 may 
disrupt receptor endocytosis via increased affinity for Cltc 
[61]. Endocytosis is essential for neuronal functioning [86] 
and deregulation of endosomal trafficking has been related 
to different neurological disorders including Huntington’s 
disease and Charcot–Marie–Tooth disease [10].
C9orf72
The function of C9orf72 is largely unknown, but previous 
work indicates that C9orf72 contains a DENN domain and 
may play a role in autophagy and endosomal trafficking 
by interacting with Rab proteins [21, 50, 92]. Co-immuno-
precipitation from SH-SY5Y cells revealed putative inter-
actions between C9orf72 and Rab1, Rab5, Rab7, Rab11, 
Ubql1, Ubqln2, hnRNPA1 and hnRNPA2B1 [21]. Our 
interactomics study, however, did not detect these interac-
tors or other proteins involved in autophagy or endocyto-
sis but rather unveiled enrichment for proteins with mito-
chondrial functions. One explanation for this apparent 
discrepancy in C9orf72 interactome composition is that it 
is strongly influenced by cell type or endogenous expres-
sion level. Although endogenous C9orf72 levels are gener-
ally low and our study used exogenous C9orf72 expression 
to detect interactors, we have performed biotin-streptavidin 
pull downs for over 40 protein baits but never detected a 
striking enrichment for mitochondrial proteins (e.g., [28, 
78, 80]). The specificity of our approach is further con-
firmed by the presence of C9orf72 in mitochondrial frac-
tions following subcellular fractionation and detection by 
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recently reported C9orf72-specific antibodies ([46]; Fig. 
S2). It should be noted that many of the currently available 
C9orf72 antibodies are rather non-specific, including some 
of those used for identifying C9orf72 interactors (Fig. 
S9) [83]. Another recent study has reported interactions 
between two different GFP-tagged C9orf72 isoforms and 
importin-B1 or Ran-GTPase in N2A cells [89]. These inter-
actors were also identified in our study, but did not pass 
our stringent selection criteria. Interestingly, non-coding 
C9ORF72 repeat expansions may cause ALS by affecting 
nuclear transport through importin- and RAN-dependent 
mechanisms [24, 40, 94]. Although neural-specific C9orf72 
knockout mice do not display motor neuron degeneration 
or motor behavior defects [46], it is possible that loss-of-
function mechanisms cooperate with gain-of-function 
defects caused by repeat expansions and that this coopera-
tion causes motor neuron degeneration through dysregula-
tion of importins and Ran-GTPases. Further work is needed 
to address these and other possible mechanisms and to dis-
sect the precise subcellular distribution of C9orf72 and its 
link to for example mitochondria and endocytotic vesicles.
FMRP is a common target in ALS pathogenesis
To show that interactomics analyses can lead to the iden-
tification of shared interactors of different ALS-associated 
proteins that are relevant for ALS pathogenesis, we focused 
on FMRP. FMRP is a translational repressor at synap-
tic sites [15] and FMRP overexpression rescues TDP-43 
toxicity in Drosophila [14]. Our study identified FMRP 
as an interactor of TDP-43, ATXN2 and FUS. Therefore, 
to explore a more general role for FMRP in ALS patho-
genesis we studied the potential link between FMRP and 
mutant FUS. We show endogenous, direct and RNA-sensi-
tive interactions between FMRP and FUS, and found that 
FMRP localizes to mutant FUS-positive cytoplasmic aggre-
gates in spinal motor neurons. FMRP has been previously 
shown to localize to mutant FUS granules in mouse fibro-
blast cells [91], but not in SH-SY5Y cells [74]. Further, 
exogenous expression of FMRP rescued defects in NMJ 
integrity and motor behavior in zebrafish embryos caused 
by mutant FUS.
How does FMRP modulate cellular defects caused by 
mutant FUS or TDP-43? Previous studies show that seques-
tration of SMN in cytosolic aggregates by mutant FUS 
causes its axonal depletion [28]. Other ALS-associated 
mutations have also been proposed to act by depleting pro-
teins from their site of action in the cell [30, 58]. However, 
mutant FUS did not cause reduced FMRP levels in mouse 
motor neuron axons or synaptosomes derived from zebrafish 
embryos. Nevertheless, protein but not mRNA expression of 
a well-characterized FMRP target, Map1b, was increased 
at the synapse. MAP1B is a microtubule stabilizing protein 
regulating NMJ morphology [71]. Overexpression of the 
Drosophila MAP1B homolog Futsch induces NMJ abnor-
malities and impaired neurotransmission [95]. Intriguingly, 
overexpression of wild-type or mutant TDP-43 causes a 
small synaptic downregulation of Futsch in Drosophila, 
which can be reversed by FMRP overexpression. These data 
together with our results suggests that strict control of syn-
aptic MAP1B expression is essential for maintaining motor 
neuron morphology and survival. Although it is unclear why 
FUS and TDP-43 have opposing effects on local translation 
of MAP1B, it is possible that both proteins affect MAP1B 
via distinct mechanisms. For example, although TDP-43 is 
present on polysomes [13], we only detected weak to no 
FUS expression in polysomal fractions (Fig. S10). But how 
do FUS mutations affect FMRP and its downstream mRNA 
targets? One possibility is that the increase in cytosolic 
FUS caused by ALS mutations leads to enhanced binding 
between FUS and FMRP, thereby preventing FMRP from 
binding to its target mRNAs on stalled polyribosomes lead-
ing to increased translation of MAP1B [15]. In line with this 
model, preliminary studies reveal enhanced binding between 
mutant FUS and FMRP and show increased expression of 
mutant as compared to wild-type FUS in FMRP granules in 
primary motor neurons (Fig. S11; A. M. B., M. K. and R. J. 
P., unpublished observations). Alternatively, FUS may alter 
the localization of FMRP at the synapse or by itself bind 
and control translation of MAP1B mRNA. Future studies 
are required to further examine the role and mechanism-of-
action of FMRP in ALS pathogenesis.
In conclusion, we report a novel dataset comprised 
interactomes of six ALS-associated proteins that will pro-
vide a framework for future studies into the pathogenic 
mechanisms underlying ALS or other diseases linked to 
the proteins studied here [e.g., frontotemporal dementia 
(FTD; C9orf72, FUS, TDP-43) or SCA2 (ATXN2)]). We 
show that the interactors of multiple different ALS-associ-
ated proteins converge on a limited number of molecular 
complexes and related processes, namely RNA metabo-
lism (ATXN2, FUS, hnRNPA1, hnRNPA2B1, MATR3 
and TDP-43), autophagy and NF-κB signaling (OPTN, 
SQSTM1, TBK1, UBQLN2 and VCP) and mitochon-
drial functioning (C9orf72). Finally, the observation that 
FMRP, a shared interactor of ATXN2, FUS, and TDP-43, 
rescues FUS toxicity in an in vivo ALS model demon-
strates that comparative interactomics analyses can aid in 
the identification and characterization of disease relevant 
proteins. This work showing that FMRP can reverse patho-
genic effects caused by mutant FUS and TDP-43 identifies 
FMRP as an interesting therapeutic target in ALS.
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